Terns Pharmaceuticals (NASDAQ:TERN) Shares Up 9.6% on Analyst Upgrade

Terns Pharmaceuticals (TERN) shares advanced 9.6% in mid-day trading after Mizuho raised its price target to $33, maintaining an "outperform" rating, a sentiment echoed by several other firms including Jefferies and Truist, which also issued "buy" ratings and increased price objectives. This positive analyst conviction follows the clinical-stage biopharmaceutical company's recent earnings report, where it posted a narrower-than-expected loss of ($0.27) EPS, beating consensus. High institutional ownership, currently at 98.26%, and significant recent investor inflows further underscore growing confidence in TERN's pipeline, which includes a Phase 1 oncology candidate.

Analysis

Terns Pharmaceuticals (TERN) experienced a significant 9.6% stock price increase on Friday, closing at $22.71, following multiple positive analyst revisions. Mizuho notably raised its price target from $32.00 to $33.00, maintaining an "outperform" rating, while Jefferies Financial Group increased its target from $28.00 to $35.00 with a "buy" rating. This upward momentum occurred on reduced trading volume, down 34% from average, suggesting conviction among existing holders rather than broad new entry.

The broader analyst community holds a "Moderate Buy" consensus rating for TERN, with an average target price of $25.63, reflecting 10 "Buy" ratings against one "Sell." This positive sentiment is partly underpinned by the company's recent Q3 earnings, where it reported an EPS of ($0.27), outperforming the consensus estimate of ($0.30) by $0.03. Despite being a clinical-stage firm with a negative P/E ratio of -21.90, the beat on earnings indicates better-than-expected financial management or operational efficiency.

Institutional investors demonstrate strong confidence in Terns, holding 98.26% of the stock, with several firms like Nuveen LLC and Walleye Capital LLC initiating or significantly increasing their positions in recent quarters. The company's pipeline, including TERN-701, a Phase 1 oncology candidate for chronic myeloid leukemia, positions it in high-growth therapeutic areas like oncology, MASH, and obesity. The stock's current trading price significantly above its 50-day ($10.12) and 200-day ($6.61) simple moving averages further underscores recent positive market perception.

Key Decisions for Investors

• Investors should monitor the progression of Terns Pharmaceuticals' clinical pipeline, particularly TERN-701, as successful trial advancements could significantly de-risk the investment and drive further upside.
• Given the high institutional ownership and strong analyst consensus, maintaining a position or considering an entry on any short-term pullbacks might be prudent, aligning with the "Moderate Buy" rating.
• While recent earnings beat expectations, the company remains unprofitable, necessitating close attention to future financial reports and cash burn rates for a clinical-stage biopharmaceutical firm.